Instrument Inactif

Autres langues Spatializer Audio Laboratories, Inc. Other OTC

Actions

US84725L3096

Cours en clôture Other OTC
- ^USD	-

14/08	Enveric Biosciences, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
05/08	Enveric Biosciences publie de nouvelles données précliniques confirmant le profil non hallucinogène de son candidat principal EB-003	CI

Autres langues

14/08	Enveric Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
14/08	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
05/08	Enveric Biosciences Reports New Preclinical Data Supporting The Non-Hallucinogenic Profile Of Lead Candidate EB-003
05/08	Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
28/07	Enveric Biosciences Provides Update On EB-003 Clinical Development And FDA Guidance
28/07	Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
16/07	Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
16/07	AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
29/06	Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
16/06	Enveric Biosciences Announces Participation in 2026 BIO International Convention
09/06	Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
02/06	Enveric Biosciences Initiates IND-Enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
02/06	Enveric Biosciences Begins Genotoxicity Testing for EB-003
02/06	Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
19/05	Enveric Biosciences reports positive preclinical results from phototoxicity analysis for lead neuroplastogen candidate Eb-003
19/05	Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
19/05	Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate EB-003
18/05	Trump's psychedelic drug order boosts investor interest with promise of faster reviews
15/05	Enveric Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/05	Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
13/05	Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
05/05	Enveric Biosciences Inc - Reports positive preclinical results for EB-003 in PTSD model
05/05	Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
27/04	SmallCap Emerge: ENVB, SMX, ANY, ELPW Across High-Growth Sectors
21/04	Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum